aXichem AB (publ), corporate registration number 556739-8663 (the "Company"), held its Annual General Meeting on Wednesday, June 17, 2026, at 10:00 a.m. in Malmö. The following is an account of the main content of the most important decisions. Complete information and documents regarding the meeting's decisions are available on the Company's website, www.axichem.com.
The Annual General Meeting resolved to adopt the presented income statement and balance sheet, as well as the consolidated income statement and consolidated balance sheet.
The Annual General Meeting resolved to dispose of the Company's results in accordance with the Board's proposal in the annual report, meaning that no dividend will be paid and that the result for the financial year 2025 will be carried forward.
The Annual General Meeting resolved to re-elect the ordinary board members Torsten Helsing, Jørn H. Berthelsen, Michael Engström and Christian Månsson, and to elect Hanne Bonge-Hansen as a new ordinary member of the board. Michael Engström was elected as new chairman of the board.
The Annual General Meeting resolved to re-elect Forvis Mazars AB as the Company's auditor for the period until the end of the 2027 Annual General Meeting. Annika Larsson will continue as the auditor in charge.
The Annual General Meeting resolved to discharge the Board members and the CEO from liability for the financial year 2025.
The Annual General Meeting resolved that the Board of Directors' fees shall be paid in eight price base amounts to the Chairman of the Board and in three price base amounts each to the other Board members. The Annual General Meeting further resolved that the auditor's fees shall be paid in accordance with an approved current account.
The Annual General Meeting resolved to authorize the Board of Directors, at the latest until the time of the next Annual General Meeting, on one or more occasions and with or without preferential rights for the shareholders, to decide on the issue of new shares, convertibles and/or warrants, provided that such an issue may not result in the Company's share capital exceeding the Company's maximum permitted share capital according to the Articles of Association. Such an issue decision may also be made with a provision for payment in kind, set-off or other conditions.
The information was submitted, through the agency of the contact person below, for publication on 17 June 2026, at 12:00CET.
Contact:
Torsten Helsing, CEO of aXichem, +46 70 686 33 55. Email: torsten.helsing@axichem.se
About aXichem:
aXichem develops, patents and markets natural analogue industrial chemicals, i.e. synthetically produced substances that have similar and comparable properties to natural substances. The Company's first product is phenylcapsaicin, which the Company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and a dietary supplement, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in dietary supplements for intestinal health, weight control and sports and exercise; and as an ingredient in dietary supplements for bioavailability enhancement of curcumin and melatonin. aXichem is listed on Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB. More information is available at www.axichem.com
